NASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $16.69 -0.35 (-2.05%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$16.69 0.00 (0.00%) As of 10/30/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dyne Therapeutics Stock (NASDAQ:DYN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$16.34▼$17.2050-Day Range$14.25▼$26.3652-Week Range$14.00▼$27.31Volume1.45 million shsAverage Volume2.94 million shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$31.29Consensus RatingModerate Buy Company Overview Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for serious muscle diseases. The company’s research is centered on conditions in which the delivery of therapeutic molecules to skeletal muscle and other tissues is a significant challenge. Dyne uses its proprietary FORCE platform to design targeted therapies intended to improve the delivery of oligonucleotides into muscle cells. The platform incorporates antibodies that bind to the transferrin receptor, which can help transport genetic medicines across cell membranes and into muscle tissue. Dyne’s pipeline includes DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping. The company was founded in 2018 and is headquartered in Waltham, Massachusetts. Dyne is led by Chief Executive Officer John Cox and serves patients through its global clinical-development programs.AI Generated. May Contain Errors. Read More Dyne Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreDYN MarketRank™: 3.633933229 of 5 starsDyne Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 192nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingDyne Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 11 buy ratings, 2 hold ratings, and 2 sell ratings.Upside PotentialDyne Therapeutics has a consensus price target of $31.29, representing about 87.5% upside from its current price of $16.69.Amount of Analyst CoverageDyne Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.59) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.06% of the float of Dyne Therapeutics has been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 7.39.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 1.97%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.24 News SentimentDyne Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Dyne Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold 163,481.68% more of their company's stock than they have bought. Specifically, they have bought $40,000.00 in company stock and sold $65,432,671.00 in company stock.Percentage Held by Insiders9.46% of the stock of Dyne Therapeutics is held by insiders.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DYN Stock News HeadlinesDyne Therapeutics (NASDAQ:DYN) Stock Gets Downgrade from OppenheimerOctober 30 at 2:18 AM | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down After Analyst DowngradeOctober 30 at 1:21 AM | americanbankingnews.comThe most dangerous moment in a financial crisisDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.November 1 at 1:00 AM | Weiss Ratings (Ad)Oppenheimer Downgrades Dyne Therapeutics to Perform From Outperform, $15 Price TargetOctober 28, 2026 | marketscreener.comMDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 22, 2026 | globenewswire.comWhy Dyne Therapeutics (DYN) Is Back In The SpotlightOctober 7, 2026 | finance.yahoo.comDyne Therapeutics (NASDAQ:DYN) Director Acquires 2,500 Shares of Company StockOctober 7, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF) and Dyne Therapeutics (DYN)October 1, 2026 | theglobeandmail.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $19.56 at the beginning of the year. Since then, DYN shares have decreased by 14.7% and is now trading at $16.69. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) issued its quarterly earnings data on Wednesday, July, 29th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.33. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $208 million in an IPO on Thursday, September 17th 2020. The company issued 12,251,578 shares at $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional investors include Profund Advisors LLC (0.04%), China Universal Asset Management Co. Ltd. (0.02%), ProShare Advisors LLC (0.01%) and Mirae Asset Global Investments Co. Ltd. (0.01%). Insiders that own company stock include Venture Fund Xi LP Atlas, Jason P Rhodes, John Cox, Oxana Beskrovnaya, Douglas Kerr, Johanna Friedl-Naderer, Wildon Farwell, Susanna Gatti High, Richard William Scalzo, Erick Lucera, Dirk Kersten, Brian S Posner and Carlo Incerti. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dyne Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Definium Therapeutics (DFTX) and Alphabet (GOOG). Company Calendar Last Earnings7/29/2026Today11/01/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DYN's financial health is in the Yellow zone, according to TradeSmith. DYN has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees258Year Founded2018Price Target and Rating Average Price Target for Dyne Therapeutics$31.29 High Price Target$50.00 Low Price Target$10.00 Potential Upside/Downside+87.5%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$446.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.30% Return on Assets-50.33% Debt Debt-to-Equity Ratio0.28 Current Ratio12.02 Quick Ratio12.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.81 per share Price / Book2.45Miscellaneous Outstanding Shares186,750,000Free Float169,080,000Market Cap$3.12 billion OptionableOptionable Beta1.12 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:DYN) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTesla pays $0 in dividends. This new fund paid $452 in one month on $5,000.Tesla has never paid shareholders a dividend, not one cent. A new fund built on Tesla's stock takes a differen...Investors Alley | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
